Celcuity stock (NASDAQ: CELC), a clinical-stage biotechnology company, experienced an extraordinary 3x surge in a single trading session, with shares rocketing from approximately $14 to a peak of $46 ...
Celcuity (CELC) is making strides with its lead therapeutic candidate, Gedatolisib, currently in Phase 3 clinical trials. It shows promising potential as a first-line treatment for HR+/HER2- advanced ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Fintel reports that on October 3, 2025, Needham reiterated coverage of Celcuity (NasdaqCM:CELC) with a Buy recommendation. Analyst Price Forecast Suggests 53.76% Upside As of September 30, 2025, the ...
Celcuity Inc. retains a 'Buy' rating as gedatolisib advances toward a likely 2026 FDA approval and commercial launch. VIKTORIA-1 phase 3 data show gedatolisib delivers superior progression-free ...
CELC is trading at record highs today after the company's big breakthrough Biotech stock Celcuity Inc (NASDAQ:CELC) is skyrocketing today, up 221% at $43.76 at last glance, after upbeat phase 3 trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results